Moderna, Inc. — Director's Dealing 2020

May 28, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2020-05-27

Reporting Person: Kim Lorence H. (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-05-27	Common Stock	M	222365	$14.22	Acquired	1424875	Direct
2020-05-27	Common Stock	M	18635	$12.21	Acquired	1443510	Direct
2020-05-27	Common Stock	S	241000	$51.13	Disposed	1202510	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-05-27	Stock Option (Right to Buy)	$12.21	M	18635	Disposed	2027-02-23	Common Stock (18635)	Direct
2020-05-27	Stock Option (Right to Buy)	$14.22	M	222365	Disposed	2028-02-28	Common Stock (222365)	Direct

Footnotes

F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F2: 25% of this option vested and became exercisable on February 22, 2018, with the remainder vesting in 12 equal quarterly installments thereafter.

F3: 458,715 of the options will vest over 4 years (25% on February 27, 2019, then quarterly for the next 3 years), 229,358 of the options will vest over 5 years (25% on February 27, 2020, then quarterly for the next 3 years), 229,358 of the options will vest over 6 years (25% on February 27, 2021, then quarterly for the next 3 years).